Cited by 150Schizophrenia research and treatmentTreatment of Major DepressionTryptophan and brain disorders

The DOI matches its Crossref record, with a small difference in title or year; 26 of the 26 references it cites were found in a registry or an index.

Minocycline as Adjunctive Therapy for Schizophrenia: An Open-Label Study

Miyaoka, Tsuyoshi, Yasukawa, Rei, Yasuda, Hideaki, Hayashida, Maiko, Inagaki, Takuji, Horiguchi, Jun·2008·Clinical Neuropharmacology

DOI 10.1097/wnf.0b013e3181593d45

Open this paper in CoChat — free account

Abstract

Minocycline is a caspase inhibitor, decreases inducible nitric oxide synthase, and has been shown to delay disease in a mouse model of neuropsychiatric disorders. Recently, we reported the antipsychotic effects of minocycline in patients with schizophrenia. In a pilot investigation, we administered minocycline (150 mg/d) for 4 weeks as an open-label adjunct to antipsychotic medication to 22 patients with schizophrenia. The Positive and Negative Syndrome Scale for schizophrenia showed statistically significant and robust clinical improvements with minocycline treatment, which were maintained at follow-up evaluation 4 weeks after the end of minocycline treatment. There were no adverse events. These results suggest that minocycline may be a safe and effective adjunct to antipsychotic medications, and that augmentation with minocycline may prove to be a viable strategy for "boosting" antipsychotic efficacy and for treating schizophrenia.

Integrity signals

Registry

Crossref · 10.1097/wnf.0b013e3181593d45

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

The Positive and Negative Syndrome Scale (PANSS) for schizophrenia.
Kay, S. R., Fiszbein, A., & Opler, L. A. (1987) · Schizophrenia Bulletin · doi:10.1093/schbul/13.2.261 · Cited by 21,378
Implications of Normal Brain Development for the Pathogenesis of Schizophrenia
Weinberger, D. R. (1987) · Archives of General Psychiatry · doi:10.1001/archpsyc.1987.01800190080012 · Cited by 3,724
Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence
Harrison, P. J., & Weinberger, D. R. (2005) · Molecular Psychiatry · doi:10.1038/sj.mp.4001558 · Cited by 2,020
Microglia: Intrinsic immuneffector cell of the brain
Gehrmann, J., Matsumoto, Y., & Kreutzberg, G. W. (1995) · Brain Research Reviews · doi:10.1016/0165-0173(94)00015-h · Cited by 1,111
Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease
Chen, M., Ona, V. O., Li, M., Ferrante, R. J., Fink, K., Zhu, S., Bian, J., Guo, L., Farrell, L. A., Hersch, S. M., et al. (2000) · Nature Medicine · doi:10.1038/77528 · Cited by 1,060
A tetracycline derivative, minocycline, reduces inflammation and protects against focal cerebral ischemia with a wide therapeutic window
Yrjänheikki, J., Kauppinen, T. M., Keinänen, R., Goldsteins, G., Chan, P. H., & Koıstınaho, J. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.23.13496 · Cited by 1,040
Minocycline, a tetracycline derivative, is neuroprotective against excitotoxicity by inhibiting activation and proliferation of microglia
Tikka, T., Fiebich, B. L., Goldsteins, G., Keinänen, R., & Koistinaho, J. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-08-02580.2001 · Cited by 958
Minocycline Prevents Nigrostriatal Dopaminergic Neurodegeneration in the MPTP Model of Parkinson’s Disease
Du, Y., Ma, Z., Lin, S., Dodel, R. C., Gao, F., Bales, K. R., Triarhou, L. C., Chernet, E., Perry, K. W., Nelson, D. L. G., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.251341998 · Cited by 789
Minocycline Provides Neuroprotection Against N -Methyl- d -aspartate Neurotoxicity by Inhibiting Microglia
Tikka, T., & Koıstınaho, J. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.12.7527 · Cited by 539
The Promise of Minocycline in Neurology
Yong, V. W., Wells, J., Giuliani, F., Casha, S., Power, C., & Metz, L. M. (2004) · The Lancet Neurology · doi:10.1016/s1474-4422(04)00937-8 · Cited by 518

Show all 26 references

Research works printed but not linked: 1

German, 2004, Regulation of apoptosis by typical and atypical antipsychotics in rat frontal cortex., Eur Neuropsychopharmacol, 55, 214S

Sorted by citations

Inflammation and immunity in schizophrenia: implications for pathophysiology and treatment
Khandaker, G. M., Cousins, L., Deakin, J., Lennox, B. R., Yolken, R., & Jones, P. B. (2015) · The Lancet Psychiatry · doi:10.1016/s2215-0366(14)00122-9 · Cited by 926
Neuroinflammation and psychiatric illness
Najjar, S., Pearlman, D. M., Alper, K., Najjar, A., & Devinsky, O. (2013) · Journal of Neuroinflammation · doi:10.1186/1742-2094-10-43 · Cited by 733
Glutamate and dopamine in schizophrenia: An update for the 21 st century
Howes, O., McCutcheon, R., & Stone, J. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881114563634 · Cited by 702
Inflammasome signaling affects anxiety- and depressive-like behavior and gut microbiome composition
Wong, M.-L., Inserra, A., Lewis, M. D., Mastronardi, C. A., Leong, L., Choo, J., Kentish, S., Xie, P., Morrison, M., Wesselingh, S. L., et al. (2016) · Molecular Psychiatry · doi:10.1038/mp.2016.46 · Cited by 568
Neuroinflammation in Schizophrenia-Related Psychosis: A PET Study
Doorduin, J., de Vries, E. F. J., Willemsen, A. T. M., de Groot, J. C., Dierckx, R., & Klein, H. C. (2009) · Journal of Nuclear Medicine · doi:10.2967/jnumed.109.066647 · Cited by 561
Cytokines and schizophrenia: microglia hypothesis of schizophrenia
Monji, A., Kato, T., & Kanba, S. (2009) · Psychiatry and Clinical Neurosciences · doi:10.1111/j.1440-1819.2009.01945.x · Cited by 508
HPA Axis in the Pathomechanism of depression and schizophrenia: new therapeutic strategies based on its participation
Mikulska, J., Juszczyk, G., Gawrońska-Grzywacz, M., & Herbet, M. (2021) · Brain Sciences · doi:10.3390/brainsci11101298 · Cited by 450
The role of pro-inflammatory cytokines in the neuroinflammation and neurogenesis of schizophrenia
Na, K., Jung, H., & Kim, Y. (2012) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2012.10.022 · Cited by 434
A Double-Blind, Randomized Study of Minocycline for the Treatment of Negative and Cognitive Symptoms in Early-Phase Schizophrenia
Levkovitz, Y., Mendlovich, S., Riwkes, S., Braw, Y., Levkovitch-Verbin, H., Gal, G., Fennig, S., Treves, I., & Kron, S. (2010) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08m04666yel · Cited by 387
Inflammation and Schizophrenia
Kirkpatrick, B. W., & Miller, B. J. (2013) · Schizophrenia Bulletin · doi:10.1093/schbul/sbt141 · Cited by 326
Neuroinflammation in schizophrenia especially focused on the role of microglia
Monji, A., Kato, T. A., Mizoguchi, Y., Horikawa, H., Seki, Y., Kasai, M., Yamauchi, Y., Yamada, S., & Kanba, S. (2013) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2011.12.002 · Cited by 314
Microglial Dysregulation in Psychiatric Disease
Frick, L. R., Williams, K., & Pittenger, C. (2013) · Clinical and Developmental Immunology · doi:10.1155/2013/608654 · Cited by 299
Minocycline benefits negative symptoms in early schizophrenia: a randomised double-blind placebo-controlled clinical trial in patients on standard treatment
Chaudhry, I. B., Hallak, J. E. C., Husain, N., Minhas, F., Stirling, J., Richardson, P., Dursun, S. M., Dunn, G., & Deakin, J. F. W. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881112444941 · Cited by 284
Cross talk: the microbiota and neurodevelopmental disorders
Kelly, J. R., Minuto, C., Cryan, J. F., Clarke, G., & Dinan, T. G. (2017) · Frontiers in Neuroscience · doi:10.3389/fnins.2017.00490 · Cited by 271
Inflammatory processes in schizophrenia: A promising neuroimmunological target for the treatment of negative/cognitive symptoms and beyond
Meyer, U., Schwarz, M., & Müller, N. (2011) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2011.06.003 · Cited by 262
The methodology of TSPO imaging with positron emission tomography
Turkheimer, F. E., Rizzo, G., Bloomfield, P. S., Howes, O., Zanotti-Fregonara, P., Bertoldo, A., & Veronese, M. (2015) · Biochemical Society Transactions · doi:10.1042/bst20150058 · Cited by 238
Evidence for a Dysregulated Immune System in the Etiology of Psychiatric Disorders
Gibney, S. M., & Drexhage, H. A. (2013) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-013-9462-8 · Cited by 245
Microglial activation and progressive brain changes in schizophrenia
Laskaris, L., Biase, M. A. D., Everall, I., Chana, G., Christopoulos, A., Skafidas, E. S., Cropley, V., & Pantelis, C. (2015) · British Journal of Pharmacology · doi:10.1111/bph.13364 · Cited by 237
The inflammation hypothesis in geriatric depression
Alexopoulos, G. S., & Morimoto, S. S. (2011) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.2672 · Cited by 237
Open-label add-on treatment trial of minocycline in fragile X syndrome.
Paribello, C., Tao, L., Folino, A., Berry-Kravis, E., Tranfaglia, M., Ethell, I. M., & Ethell, D. W. (2010) · BMC Neurology · doi:10.1186/1471-2377-10-91 · Cited by 223
Microglia Gone Rogue: Impacts on Psychiatric Disorders across the Lifespan
Tay, T. L., Béchade, C., D’Andrea, I., St‐Pierre, M., Henry, M. S., Roumier, A., & Tremblay, M. (2018) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2017.00421 · Cited by 217
Minocycline as adjunctive therapy for patients with unipolar psychotic depression: An open-label study
Miyaoka, T., Wake, R., Furuya, M., Liaury, K., Ieda, M., Kawakami, K., Tsuchie, K., Taki, M., Ishihara, K., Araki, T., et al. (2012) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2012.02.002 · Cited by 212
Self-citation
Novel therapeutic targets in depression: Minocycline as a candidate treatment
Soczynska, J. K., Mansur, R. B., Brietzke, E. M., Swardfager, W., Kennedy, S. H., Woldeyohannes, H. O., Powell, A. M., Manierka, M. S., & McIntyre, R. S. (2012) · Behavioural Brain Research · doi:10.1016/j.bbr.2012.07.026 · Cited by 192
Minocycline rescues decrease in neurogenesis, increase in microglia cytokines and deficits in sensorimotor gating in an animal model of schizophrenia
Mattei, D., Djodari-Irani, A., Hadar, R., Pelz, A., de Cossío, L. F., Goetz, T., Matyash, M., Kettenmann, H., Winter, C., & Wolf, S. A. (2014) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2014.01.019 · Cited by 195
Effectiveness and tolerance of anti‐inflammatory drugs' add‐on therapy in major mental disorders: a systematic qualitative review
Fond, G. B., Hamdani, N., Kapczinski, F. P., Boukouaci, W., Drancourt, N., Dargél, A., Oliveira, J., Guen, E. L., Marlinge, E., Tamouza, R., et al. (2013) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12211 · Cited by 175
The benefit of minocycline on negative symptoms of schizophrenia in patients with recent-onset psychosis (BeneMin): a randomised, double-blind, placebo-controlled trial
Deakin, J. F. W., John Suckling, A., Barnes, T. R. E., Byrne, K., Chaudhry, I. B., Dazzan, P., Drake, R., Giordano, A., Husain, N., Jones, P. B., et al. (2018) · The Lancet Psychiatry · doi:10.1016/s2215-0366(18)30345-6 · Cited by 174
The Perineuronal ‘Safety’ Net? Perineuronal Net Abnormalities in Neurological Disorders
Wen, T. H., Binder, D. K., Ethell, I. M., & Razak, K. A. (2018) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2018.00270 · Cited by 170
Prenatal Immune Challenge in Mice Leads to Partly Sex-Dependent Behavioral, Microglial, and Molecular Abnormalities Associated with Schizophrenia
Hui, C. W., St-Pierre, A., Hajj, H. E., Remy, Y., Hébert, S. S., Luheshi, G. N., Srivastava, L. K., & Tremblay, M. (2018) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2018.00013 · Cited by 166
On the translocation of bacteria and their lipopolysaccharides between blood and peripheral locations in chronic, inflammatory diseases: the central roles of LPS and LPS-induced cell death
Kell, D. B., & Pretorius, E. (2015) · Integrative Biology · doi:10.1039/c5ib00158g · Cited by 170
Therapeutic Strategies for Treatment of Inflammation-related Depression
Adžić, M., Brkic, Z., Mitić, M., Francija, E., Jovicic, M. J., Radulović, J., & Marić, N. P. (2017) · Current Neuropharmacology · doi:10.2174/1570159x15666170828163048 · Cited by 162
Oligodendroglial alterations and the role of microglia in white matter injury: relevance to schizophrenia
Chew, L.-J., Fusar-Poli, P., & Schmitz, T. (2013) · Developmental Neuroscience · doi:10.1159/000346157 · Cited by 154
Polypharmacy in schizophrenia
Zink, M., Englisch, S., & Meyer‐Lindenberg, A. (2010) · Current Opinion in Psychiatry · doi:10.1097/yco.0b013e3283366427 · Cited by 143
Minocycline supplementation for treatment of negative symptoms in early-phase schizophrenia: A double blind, randomized, controlled trial
Liu, F., Guo, X., Wu, R., Ou, J., Zheng, Y., Zhang, B., Xie, L., Zhang, L., Yang, L., Yang, S., et al. (2014) · Schizophrenia Research · doi:10.1016/j.schres.2014.01.011 · Cited by 135
Methylation Patterns in Whole Blood Correlate With Symptoms in Schizophrenia Patients
Liu, J., Chen, J., Ehrlich, S., Walton, E., White, T. J. H., Perrone‐Bizzozero, N. I., Bustillo, J., Turner, J. A., & Calhoun, V. D. (2013) · Schizophrenia Bulletin · doi:10.1093/schbul/sbt080 · Cited by 134
Minocycline: Therapeutic Potential in Psychiatry
Dean, O. M., Data-Franco, J., Giorlando, F., & Berk, M. (2012) · CNS Drugs · doi:10.2165/11632000-000000000-00000 · Cited by 131
The role of the gut microbiome in the development of schizophrenia
Kelly, J. R., Minuto, C., Cryan, J. F., Clarke, G. A., & Dinan, T. G. (2020) · Schizophrenia Research · doi:10.1016/j.schres.2020.02.010 · Cited by 121
Minocycline add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: randomized double-blind placebo-controlled study.
Khodaie-Ardakani, M.-R., Mirshafiee, O., Farokhnia, M., Tajdini, M., Hosseini, S.-M.-R., Modabbernia, A., Rezaei, F., Salehi, B., Yekehtaz, H., Ashrafi, M., et al. (2014) · Psychiatry Research · doi:10.1016/j.psychres.2013.12.051 · Cited by 104
Putative neuroprotective agents in neuropsychiatric disorders
Dodd, S., Maes, M. H. J., Anderson, G., Dean, O. M., Moylan, S., & Berk, M. (2012) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2012.11.007 · Cited by 105
Adjunctive Minocycline in Clozapine-Treated Schizophrenia Patients With Persistent Symptoms
Kelly, D. L., Sullivan, K. M., McEvoy, J. P., McMahon, R. P., Wehring, H. J., Gold, J. M., Liu, F., Warfel, D. T., Vyas, G. R., Richardson, C. M., et al. (2015) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000345 · Cited by 103
The interplay of dopamine metabolism abnormalities and mitochondrial defects in the pathogenesis of schizophrenia
Xu, H., & Yang, F. (2022) · Translational Psychiatry · doi:10.1038/s41398-022-02233-0 · Cited by 114
The cannabinoid system and microglia in health and disease
Duffy, S. S., Hayes, J. P., Fiore, N. T., & Moalem‐Taylor, G. (2021) · Neuropharmacology · doi:10.1016/j.neuropharm.2021.108555 · Cited by 103
Minocycline in neurodegenerative and psychiatric diseases: An update
Romero‐Miguel, D., Lamanna‐Rama, N., Casquero‐Veiga, M., Gómez‐Rangel, V., Desco, M., & Soto‐Montenegro, M. L. (2020) · European Journal of Neurology · doi:10.1111/ene.14642 · Cited by 94
Minocycline alleviates behavioral deficits and inhibits microglial activation in the offspring of pregnant mice after administration of polyriboinosinic–polyribocytidilic acid
Zhu, F., Zheng, Y., Liu, Y. H., Zhang, X., & Zhao, J. (2014) · Psychiatry Research · doi:10.1016/j.psychres.2014.06.046 · Cited by 92
Evidence for an Immune Role on Cognition in Schizophrenia: A Systematic Review
Ribeiro-Santos, R., Teixeira, A. L., & Salgado, J. V. (2014) · Current Neuropharmacology · doi:10.2174/1570159x1203140511160832 · Cited by 86
GABA receptor subunit distribution and FMRP–mGluR5 signaling abnormalities in the cerebellum of subjects with schizophrenia, mood disorders, and autism
Fatemi, S. H., & Folsom, T. D. (2014) · Schizophrenia Research · doi:10.1016/j.schres.2014.10.010 · Cited by 86
Adjunctive minocycline for schizophrenia: A meta-analysis of randomized controlled trials
Xiang, Y.-Q., Zheng, W., Wang, S.-B., Yang, X.-H., Cai, D.-B., Ng, C. H., Ungvari, G. S., Kelly, D. L., Xu, W.-Y., & Xiang, Y.-T. (2016) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2016.11.012 · Cited by 83
Minocycline in Acne Vulgaris
Ochsendorf, F. R. (2010) · American Journal of Clinical Dermatology · doi:10.2165/11319280-000000000-00000 · Cited by 80
Are the emergence of affective disturbances in neuropathic pain states contingent on supraspinal neuroinflammation?
Fiore, N. T., & Austin, P. J. (2016) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2016.04.012 · Cited by 80
Systematic review and meta-analysis of the efficacy and safety of minocycline in schizophrenia
Solmi, M., Veronese, N., Thapa, N., Facchini, S., Stubbs, B., Fornaro, M., Carvalho, A. F., & Correll, C. U. (2017) · CNS Spectrums · doi:10.1017/s1092852916000638 · Cited by 78
Therapeutic effects of minocycline on mild-to-moderate depression in HIV patients
Emadi-Kouchak, H., Mohammadinejad, P., Asadollahi‐Amin, A., Rasoulinejad, M., Zeinoddini, A., Yalda, A., & Akhondzadeh, S. (2015) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000098 · Cited by 76
The effectiveness of multi-target agents in schizophrenia and mood disorders: Relevance of receptor signature to clinical action
Wong, E. H. F., Tarazi, F. I., & Shahid, M. (2010) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2010.02.001 · Cited by 78
Minocycline and aspirin in the treatment of bipolar depression: a protocol for a proof-of-concept, randomised, double-blind, placebo-controlled, 2×2 clinical trial
Savitz, J. B., Preskorn, S., Teague, T. K., Drevets, D. A., Yates, W. R., & Drevets, W. (2012) · BMJ Open · doi:10.1136/bmjopen-2011-000643 · Cited by 73
Structural and Functional Deviations of the Hippocampus in Schizophrenia and Schizophrenia Animal Models
Wegrzyn, D., Juckel, G., & Faissner, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23105482 · Cited by 80
Clinical management of negative symptoms of schizophrenia: An update
Tsapakis, E.-M., Dimopoulou, T., & Tarazi, F. I. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2015.06.008 · Cited by 76
Anti-inflammatory signaling in schizophrenia
Meyer, U. (2011) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2011.05.014 · Cited by 72
Neuroinflammation is associated with changes in glial mGluR5 expression and the development of neonatal excitotoxic lesions
Drouin‐Ouellet, J., Brownell, A., Saint‐Pierre, M., Fasano, C., Émond, V., Trudeau, L., Lévesque, D., & Cicchetti, F. (2010) · Glia · doi:10.1002/glia.21086 · Cited by 72
Resolving and Rescuing Developmental Miswiring in a Mouse Model of Cognitive Impairment
Chini, M., Pöpplau, J. A., Lindemann, C., Carol-Perdiguer, L., Hnida, M., Oberlander, V. C., Xu, X., Ahlbeck, J., Bitzenhofer, S. H., Mulert, C., et al. (2019) · Neuron · doi:10.1016/j.neuron.2019.09.042 · Cited by 71
The Neuroimmunology of Schizophrenia
Annya, M., Smyth, Stephen, M., & Lawrie, S. M. (2013) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.2013.11.3.107 · Cited by 68
Annual Research Review: The neuroinflammation hypothesis for stress and psychopathology in children – developmental psychoneuroimmunology
O’Connor, T. G., Moynihan, J. A., & Caserta, M. T. (2013) · Journal of Child Psychology and Psychiatry · doi:10.1111/jcpp.12187 · Cited by 68
Glutamate-N-methyl-D-aspartate receptor modulation and minocycline for the treatment of patients with schizophrenia: an update
Chaves, C., de Marque, C. R., Trzesniak, C. M. F., de Sousa, J. P. M., Zuardi, A. W., Crippa, J. A. S., Dursun, S. M., & Hallak, J. E. C. (2009) · Brazilian Journal of Medical and Biological Research · doi:10.1590/s0100-879x2009001100002 · Cited by 64
Aripiprazole inhibits superoxide generation from phorbol-myristate-acetate (PMA)-stimulated microglia in vitro: Implication for antioxidative psychotropic actions via microglia
Kato, T. A., Monji, A., Yasukawa, K., Mizoguchi, Y., Horikawa, H., Seki, Y., Hashioka, S., Han, Y.-H., Kasai, M., Sonoda, N., et al. (2011) · Schizophrenia Research · doi:10.1016/j.schres.2011.03.019 · Cited by 63
Protocol and rationale-the efficacy of minocycline as an adjunctive treatment for major depressive disorder: a double blind, randomised, placebo controlled trial
Dean, O. M., Maes, M., Ashton, M., Berk, L., Kanchanatawan, B., Sughondhabirom, A., Tangwongchai, S., Ng, C., Dowling, N., Malhi, G. S., et al. (2014) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.2014.12.3.180 · Cited by 58
Morphological features of microglial cells in the hippocampal dentate gyrus of Gunn rat: a possible schizophrenia animal model
Liaury, K., Miyaoka, T., Tsumori, T., Furuya, M., Wake, R., Ieda, M., Tsuchie, K., Taki, M., Ishihara, K., Tanra, A. J., et al. (2012) · Journal of Neuroinflammation · doi:10.1186/1742-2094-9-56 · Cited by 56
Self-citation
Adjunct Treatments for Schizophrenia and Bipolar Disorder: What to Try When You Are Out of Ideas
Torrey, E. F., & Davis, J. M. (2011) · Clinical Schizophrenia & Related Psychoses · doi:10.3371/csrp.5.4.5 · Cited by 56
The antibiotic minocycline prevents methamphetamine-induced rewarding effects in mice
Fujita, Y., Kunitachi, S., Iyo, M., & Hashimoto, K. (2012) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2012.01.005 · Cited by 56
Roles of inflammation in intrinsic pathophysiology and antipsychotic drug-induced metabolic disturbances of schizophrenia
Prestwood, T. R., Asgariroozbehani, R., Wu, S., Agarwal, S. M., Logan, R. W., Ballon, J. S., Hahn, M., & Freyberg, Z. (2021) · Behavioural Brain Research · doi:10.1016/j.bbr.2020.113101 · Cited by 67
Minocycline as Adjunctive Treatment to Risperidone in Children with Autistic Disorder: A Randomized, Double-Blind Placebo-Controlled Trial
Ghaleiha, A., Alikhani, R., Kazemi, M.-R., Mohammadi, M.-R., Mohammadinejad, P., Zeinoddini, A., Hamedi, M., Shahriari, M., Keshavarzi, Z., & Akhondzadeh, S. (2016) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2015.0175 · Cited by 60
Doxycycline prevents and reverses schizophrenic-like behaviors induced by ketamine in mice via modulation of oxidative, nitrergic and cholinergic pathways
Ben‐Azu, B., Omogbiya, I. A., Aderibigbe, A. O., Umukoro, S., Ajayi, A. M., & Iwalewa, E. O. (2018) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2018.02.007 · Cited by 52
Autoimmune phenotypes in schizophrenia reveal novel treatment targets
Severance, E. G., Dickerson, F., & Yolken, R. H. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.05.005 · Cited by 52
Introducing directly induced microglia-like (iMG) cells from fresh human monocytes: a novel translational research tool for psychiatric disorders
Ohgidani, M., Kato, T. A., & Kanba, S. (2015) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2015.00184 · Cited by 52
Minocycline affects cocaine sensitization in mice
Chen, H., Uz, T., & Manev, H. (2009) · Neuroscience Letters · doi:10.1016/j.neulet.2009.01.078 · Cited by 49
The effect of minocycline on symptoms in schizophrenia: Results from a randomized controlled trial
Weiser, M., Levi, L. W., Burshtein, S., Chiriță, R., Cirjaliu, D., Gonen, I., Yolken, R. H., Davidson, M., Zamora, D., & Davis, J. M. (2018) · Schizophrenia Research · doi:10.1016/j.schres.2018.10.023 · Cited by 48
Use of Yokukansan (TJ‐54) in the treatment of neurological disorders: a review
de Caires, S., & Steenkamp, V. (2010) · Phytotherapy Research · doi:10.1002/ptr.3146 · Cited by 45
Profile of minocycline and its potential in the treatment of schizophrenia
Zhang, L., & Zhao, J. (2014) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s64236 · Cited by 45
Adjunct minocycline to clozapine treated patients with persistent schizophrenia symptoms
Kelly, D. L., Vyas, G. R., Richardson, C. M., Koola, M. M., McMahon, R. P., Buchanan, R. W., & Wehring, H. J. (2011) · Schizophrenia Research · doi:10.1016/j.schres.2011.08.005 · Cited by 44
Microglial functional alteration and increased diversity in the challenged brain: Insights into novel targets for intervention
Tremblay, M.-È. (2021) · Brain, Behavior, & Immunity - Health · doi:10.1016/j.bbih.2021.100301 · Cited by 42
Effects of minocycline add-on treatment on brain morphometry and cerebral perfusion in recent-onset schizophrenia
Chaves, C., Marque, C. R., Maia-de-Oliveira, J. P., Wichert-Ana, L., Ferrari, T. B., Santos, A. C., Araújo, D., Machado-de-Sousa, J. P., Bressan, R. A., Elkis, H., et al. (2015) · Schizophrenia Research · doi:10.1016/j.schres.2014.11.031 · Cited by 41
Minocycline improves recognition memory and attenuates microglial activation in Gunn rat: A possible hyperbilirubinemia-induced animal model of schizophrenia
Liaury, K., Miyaoka, T., Tsumori, T., Furuya, M., Hashioka, S., Wake, R., Tsuchie, K., Fukushima, M., Limoa, E., Tanra, A. J., et al. (2014) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2013.12.017 · Cited by 40
Self-citation
Importance of kynurenine 3-monooxygenase for spontaneous firing and pharmacological responses of midbrain dopamine neurons: Relevance for schizophrenia
Tufvesson‐Alm, M., Schwieler, L., Schwarcz, R. M., Goiny, M., Erhardt, S., & Engberg, G. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.06.003 · Cited by 39
Minocycline Does Not Decrease Intensity of Neuropathic Pain, but Improves Its Affective Dimension
Sumitani, M., Ueda, H., Hozumi, J., Inoue, R., Kogure, T., Ogata, T., & Yamada, Y. (2015) · Journal of Pain & Palliative Care Pharmacotherapy · doi:10.3109/15360288.2014.1003674 · Cited by 37
Adjunctive minocycline for major mental disorders: A systematic review
Zheng, W., Zhu, X., Zhang, Q., Cheng, G., Cai, D.-B., He, J., Ng, C. H., Ungvari, G. S., Peng, X.-J., Ning, Y., et al. (2019) · Journal of Psychopharmacology · doi:10.1177/0269881119858286 · Cited by 38
Microglial activation in schizophrenia and minocycline treatment
Hashimoto, K. (2008) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2008.06.012 · Cited by 35
Glutamatergic agents for schizophrenia: current evidence and perspectives
Zink, M., & Correll, C. U. (2015) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2015.1040393 · Cited by 36
Neuroinflammation and oxidative stress in schizophrenia: are these opportunities for repurposing?
Ansari, Z., Pawar, S. R., & Seetharaman, R. (2021) · Postgraduate Medicine · doi:10.1080/00325481.2021.2006514 · Cited by 35
Minocycline Modulates Human Social Decision-Making: Possible Impact of Microglia on Personality-Oriented Social Behaviors
Kato, T. A., Watabe, M., Tsuboi, S., Ishikawa, K., Hashiya, K., Monji, A., Utsumi, H., & Kanba, S. (2012) · PLoS ONE · doi:10.1371/journal.pone.0040461 · Cited by 34
A case of methamphetamine use disorder treated with the antibiotic drug minocycline
Tanibuchi, Y., Shimagami, M., Fukami, G., Sekine, Y., Iyo, M., & Hashimoto, K. (2010) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2009.12.005 · Cited by 33
Deep rTMS Mitigates Behavioral and Neuropathologic Anomalies in Cuprizone-Exposed Mice Through Reducing Microglial Proinflammatory Cytokines
Liu, Y., Su, Y., Guo, F., Zhang, H., Zhao, Y., Huang, Q., & Xu, H. (2020) · Frontiers in Integrative Neuroscience · doi:10.3389/fnint.2020.556839 · Cited by 35
Beyond Dopamine: Glutamate as a Target for Future Antipsychotics
Sendt, K.-V., Giaroli, G., & Tracy, D. K. (2012) · ISRN Pharmacology · doi:10.5402/2012/427267 · Cited by 34
Significance of NMDA receptor-related glutamatergic amino acid levels in peripheral blood of patients with schizophrenia
Ohnuma, T., & Arai, H. (2010) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2010.08.027 · Cited by 31
Granisetron as an add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: Randomized double-blind placebo-controlled study
Ardakani, M. R. K., Seddighi, S., Modabbernia, A., Rezaei, F., Salehi, B., Ashrafi, M., Shams‐Alizadeh, N., Mohammad-karimi, M., Esfandiari, G.-R., Hajiaghaee, R., et al. (2013) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2013.01.011 · Cited by 29
l-lysine as an adjunct to risperidone in patients with chronic schizophrenia: A double-blind, placebo-controlled, randomized trial
Zeinoddini, A., Ahadi, M., Farokhnia, M., Rezaei, F., Tabrizi, M. H., & Akhondzadeh, S. (2014) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2014.08.016 · Cited by 27
L-lysine as adjunctive treatment in patients with schizophrenia: a single-blinded, randomized, cross-over pilot study
Wass, C., Klamer, D., Katsarogiannis, E., Pålsson, E., Svensson, L., Fejgin, K., Bogren, I.-B., Engel, J. A., & Rembeck, B. (2011) · BMC Medicine · doi:10.1186/1741-7015-9-40 · Cited by 25
Functional neuroimaging of minocycline's effect in a patient with schizophrenia
Chaves, C., de Marque, C. R., Wichert‐Ana, L., Maia‐de‐Oliveira, J. P., Itikawa, E. N., Crippa, J. A. S., Zuardi, A. W., Todd, K. G., Baker, G. B., Dursun, S. M., et al. (2010) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2010.01.020 · Cited by 23
Promising use of minocycline augmentation with clozapine in treatment-resistant schizophrenia
Qurashi, I., Collins, J., Chaudhry, I. B., & Husain, N. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881114527358 · Cited by 22
Clinical Trials and Therapeutic Rationale for Drug Repurposing in Schizophrenia
Lago, S. G., & Bahn, S. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00205 · Cited by 23
Systematic Review of the Therapeutic Role of Apoptotic Inhibitors in Neurodegeneration and Their Potential Use in Schizophrenia
Morén, C., Treder, N., Martínez-Pinteño, A., Rodríguez, N., Arbelo, N., Madero, S., Gómez, M., Mas, S., Gassó, P., & Parellada, E. (2022) · Antioxidants · doi:10.3390/antiox11112275 · Cited by 22
Immunomodulatory Effects of Clozapine: More Than Just a Side Effect in Schizophrenia
Amerio, A., Magnani, L., Arduino, G., Fesce, F., de Filippis, R., Parise, A., Costanza, A., Nguyen, K. D., Saverino, D., Berardis, D. D., et al. (2023) · Current Neuropharmacology · doi:10.2174/1570159x22666231128101725 · Cited by 21
Minocycline decreases CD36 and increases CD44 in LPS-induced microglia
Hashemi-monfared, A., Firouzi, M., Bahrami, Z., Zahednasab, H., & Harirchian, M. H. (2018) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2018.01.010 · Cited by 19
Adjuvant therapy with minocycline for schizophrenia (The MINOS Trial): study protocol for a double-blind randomized placebo-controlled trial
Fekadu, A., Mesfin, M., Medhin, G., Alem, A., Teferra, S., Gebre-Eyesus, T., Seboxa, T., Assefa, A., Hussein, J., Lemma, M. T., et al. (2013) · Trials · doi:10.1186/1745-6215-14-406 · Cited by 19
Neuro‐Immune Crosstalk: Molecular Mechanisms, Biological Functions, Diseases, and Therapeutic Targets
Guo, X., Liu, H. N., Song, Y., Wang, J., Liu, D., Zheng, Z., Li, J., Li, B., Song, A., He, W., et al. (2026) · MedComm · doi:10.1002/mco2.70497 · Cited by 26

Authors: Miyaoka, T., Yasukawa, R., Yasuda, H., Hayashida, M., Inagaki, T., & Horiguchi, J.
Affiliations: Shimane University (JP)
Corresponding author: Miyaoka, Tsuyoshi
ORCID: Miyaoka, Tsuyoshi
Hayashida, Maiko
Inagaki, Takuji
Horiguchi, Jun
Venue: Clinical Neuropharmacology
Publisher: Ovid Technologies (Wolters Kluwer Health)
Published: 2008-09
Volume: 31
Issue: 5
Pages: 287-292
ISSN: 0362-5664 (ISSN-L)
DOI: 10.1097/wnf.0b013e3181593d45
OpenAlex: W2018922612
Cited by: 146
References: 26
Citations by year: 2026: 1 · 2025: 3 · 2024: 3 · 2023: 5 · 2022: 4 · 2021: 6 · 2020: 5 · 2019: 5 · 2018: 14 · 2017: 7 · 2016: 9 · 2015: 14 · 2014: 15 · 2013: 14 · 2012: 13
FWCI: 6.55
Type: journal article
Language: en
Open access: closed
Locations: Clinical Neuropharmacology (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
Keywords: minocycline, schizophrenia, adjunctive therapy, antipsychotic augmentation, caspase inhibition, inducible nitric oxide synthase, antipsychotic efficacy
MeSH terms: Adult, Female, Follow-Up Studies, Humans, Male, Middle Aged, Minocycline, Pilot Projects, Schizophrenia, Schizophrenic Psychology, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Minocycline as Adjunctive Therapy for Schizophrenia: An Open-Label Study

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks